A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants with Alzheimer's Disease
Lay Description
Category
- IRB Number
- 20220239HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Floyd Jones
+1 (210) 450-3158
jonesfa@uthscsa.edu
Floyd Jones
+1 (210) 450-3158
jonesfa@uthscsa.edu
Principal Investigator
Arash Salardini